530125 — Samrat Pharmachem Income Statement
0.000.00%
- IN₹834.53m
- IN₹928.43m
- IN₹2.86bn
- 69
- 57
- 21
- 48
Annual income statement for Samrat Pharmachem, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,790 | 2,218 | 3,106 | 2,816 | 2,859 |
| Cost of Revenue | |||||
| Gross Profit | 148 | 319 | 328 | 113 | 191 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,709 | 1,981 | 2,874 | 2,798 | 2,763 |
| Operating Profit | 81.6 | 237 | 233 | 18.2 | 95.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 73.4 | 236 | 225 | 25.2 | 98.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 53.3 | 172 | 166 | 21.6 | 71.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 53.3 | 172 | 166 | 21.6 | 71.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 53.3 | 172 | 166 | 21.6 | 71.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 17.3 | 55.7 | 53.8 | 7 | 23 |
| Dividends per Share |